NCT06922253View on ClinicalTrials.gov

Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2024

Primary Completion Date

January 20, 2025

Study Completion Date

March 17, 2025

Conditions

Chronic Heart Failure

Interventions

DRUG

Sacubitril and Valsartan-Test product

1 tablet of 97 mg Sacubitril / 103 mg Valsartan

DRUG

Sacubitril and Valsartan-Reference product

1 tablet of 97 mg Sacubitril / 103 mg Valsartan

Trial Locations (1)

380 051

Veeda Clinical Research Ltd., Ahmedabad

All Listed Sponsors

lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT06922253 - Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg) | Biotech Hunter | Biotech Hunter